Dr. A. Beck is Director of Antibody Physico-Chemistry and member of the board of directors of the Centre d’Immunologie Pierre Fabre (CIPF). He contributed to the R&D of anticancer mAbs (dalotuzumab/IGF-1R with Merck, h224G11/cMet with Abbott, h515H7/CXCR4, h6F4/JAM-A), vaccines and peptides. He is inventor on 16 patents, author of 80 publications, associate editor of mAbs (www.landesbioscience.com) and guest editor for special issues on mAbs (Nat Rev Immunol, Curr Pharm Biotech, Medecine/ Sciences and Meth Mol Biol). He has contributed to 130 scientific meetings as chairman, invited speaker, panelist, moderator, advisor, and/or organizer. He is also regularly invited to boards of experts by the WHO, the EMA, the European Commission, Funding Agencies (Czech, Dutch, France, Ontario, New Zealand) and bio-clusters (Alsace Biovalley, CLARA, Genopole, LyonBiopole).